Posted by Michael Wonder on 08 Jul 2021
Y-mAbs announces NMPA submission of BLA for Danyelza (naxitamab-gqgk) in China
6 July 2021 - Y-mAbs Therapeutics today announced that SciClone Pharmaceuticals has submitted the biologics license application for Danyelza (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the National Medical Products Administration of China.
